Revolution Medicines Inc

Latest Results (16.11.2025):

Revolution Medicines Inc reported its Third Quarter 2025 financial results along with significant progress in its clinical programs for RAS-addicted cancers. The company demonstrated robust cash resources, increased research and development (R&D) spending, and higher general and administrative (G&A) expenses compared to the previous year, alongside strategic advancements in its clinical trials, regulatory designations, and leadership appointments.

Financial Performance Highlights

The company reported a cash position of $1.93 billion as of September 30, 2025, bolstered by a $250 million royalty monetization tranche, with an additional $1.75 billion in committed future capital. R&D expenses increased to $262.5 million from $151.8 million year-over-year, while G&A expenses rose to $52.8 million from $24.0 million. Net loss widened to $305.2 million compared to $156.3 million in Q3 2024, and full year 2025 GAAP net loss guidance remains between $1.03 billion and $1.09 billion.

Clinical and Pipeline Updates

Revolution Medicines is advancing its RAS-targeted portfolio with progress on pivotal trials, including RASolute 302 for previously treated PDAC, which is nearing complete global enrollment and is on track for a 2026 data readout. The initiation of Phase 3 trials RASolute 304 (adjuvant treatment for resectable PDAC) and the forthcoming RASolute 303 for first line metastatic PDAC, along with expanded enrollment in the NSCLC trial, underscore the company’s commitment to developing daraxonrasib and other mutant-selective inhibitors.

Corporate and Leadership Updates

The company strengthened its global development and commercialization capabilities with new leadership appointments, including a new chief development officer and regional general managers for the U.S. and Europe. These strategic hires are set to support the company’s expanding late-stage development activities and commercialization efforts.

Financial Guidance and Webcast Information

In addition to reiterating its full year 2025 net loss guidance of $1.03 billion to $1.09 billion, Revolution Medicines announced an upcoming webcast on November 5, 2025, at 4:30 p.m. Eastern Time, where further details of its financial and operational progress will be discussed.